Skip to main content
Erschienen in: Rheumatology International 10/2019

23.08.2019 | Comorbidities

Clinical characteristics and prognosis of polymyositis and dermatomyositis associated with malignancy: a 25-year retrospective study

verfasst von: Kyoko Motomura, Hiroyuki Yamashita, Saeko Yamada, Yuko Takahashi, Hiroshi Kaneko

Erschienen in: Rheumatology International | Ausgabe 10/2019

Einloggen, um Zugang zu erhalten

Abstract

The objective of this study was to identify factors predictive of malignancy in patients with polymyositis (PM) and dermatomyositis (DM) in Japan. We conducted a retrospective study of PM and DM patients who were admitted to our hospital between January 1992 and September 2017. Among 134 patients, 29 (21.6%) were diagnosed with cancer in the 3 years prior to and 3 years after the initial diagnosis of PM or DM. According to multivariate analyses, male sex [odds ratio (OR) = 3.65, p = 0.03], old age (OR = 1.05, p = 0.02), and a past history of diabetes mellitus (OR = 10.4, p = 0.005) were associated with an increased risk of malignancy. The absence of interstitial lung disease (ILD) (OR = 0.25, p = 0.03) was also associated with an increased risk of malignancy. Diabetes mellitus was observed in 28.6% of PM and DM patients with malignancy, but in only 7.3% of those with malignancy. Survival was significantly lower in patients with malignancy than in those without malignancy (p < 0.001). Independent factors associated with malignancies in patients with PM or DM were male sex, old age, the absence of ILD, and, especially, a past history of diabetes mellitus.
Literatur
1.
Zurück zum Zitat Stertz G (1916) Polymyositis. Berl Klin Wochenschr 53:489 Stertz G (1916) Polymyositis. Berl Klin Wochenschr 53:489
2.
Zurück zum Zitat Antiochos BB, Brown LA, Li Z, Tosteson TD, Wortmann RL, Rigby WF (2009) Malignancy is associated with dermatomyositis but not polymyositis in Northern New England, USA. J Rheumatol 36:2704–2710CrossRefPubMed Antiochos BB, Brown LA, Li Z, Tosteson TD, Wortmann RL, Rigby WF (2009) Malignancy is associated with dermatomyositis but not polymyositis in Northern New England, USA. J Rheumatol 36:2704–2710CrossRefPubMed
3.
Zurück zum Zitat András C, Ponyi A, Constantin T, Csiki Z, Szekanecz E, Szodoray P et al (2008) Dermatomyositis and Polymyositis associated with malignancy: a 21-year retrospective study. J Rheumatol 35:438–444PubMed András C, Ponyi A, Constantin T, Csiki Z, Szekanecz E, Szodoray P et al (2008) Dermatomyositis and Polymyositis associated with malignancy: a 21-year retrospective study. J Rheumatol 35:438–444PubMed
4.
Zurück zum Zitat So MW, Koo BS, Kim YG, Lee CK, Yoo B (2011) Idiopathic inflammatory myopathy associated with malignancy: a retrospective cohort of 151 Korean patients with dermatomyositis and polymyositis. J Rheumatol 38(11):2432–2435CrossRefPubMed So MW, Koo BS, Kim YG, Lee CK, Yoo B (2011) Idiopathic inflammatory myopathy associated with malignancy: a retrospective cohort of 151 Korean patients with dermatomyositis and polymyositis. J Rheumatol 38(11):2432–2435CrossRefPubMed
5.
Zurück zum Zitat Fang YF, Wu YJ, Kuo CF, Luo SF, Yu KH (2016) Malignancy in dermatomyositis and polymyositis: analysis of 192 patients. Clin Rheumatol 35(8):1977–1984CrossRefPubMed Fang YF, Wu YJ, Kuo CF, Luo SF, Yu KH (2016) Malignancy in dermatomyositis and polymyositis: analysis of 192 patients. Clin Rheumatol 35(8):1977–1984CrossRefPubMed
6.
Zurück zum Zitat Wang J, Guo G, Chen G, Wu B, Lu L, Bao L (2013) Meta-analysis of the association of dermatomyositis and polymyositis with cancer. Br J Dermatol 169:838–847CrossRefPubMed Wang J, Guo G, Chen G, Wu B, Lu L, Bao L (2013) Meta-analysis of the association of dermatomyositis and polymyositis with cancer. Br J Dermatol 169:838–847CrossRefPubMed
7.
Zurück zum Zitat Ponyi A, Constantin T, Garami M, András C, Tállai B, Váncsa A et al (2005) Cancer-associated myositis:clinical features and prognostic signs. Ann N Y Acad Sci 1051:64–71CrossRefPubMed Ponyi A, Constantin T, Garami M, András C, Tállai B, Váncsa A et al (2005) Cancer-associated myositis:clinical features and prognostic signs. Ann N Y Acad Sci 1051:64–71CrossRefPubMed
8.
Zurück zum Zitat Fardet L, Dupuy A, Gain M, Kettaneh A, Chérin P, Bachelez H et al (2009) Factors associated with underlying malignancy in a retrospective cohort of 121 patients with dermatomyositis. Medicine (Baltimore). 88(2):91–97CrossRefPubMed Fardet L, Dupuy A, Gain M, Kettaneh A, Chérin P, Bachelez H et al (2009) Factors associated with underlying malignancy in a retrospective cohort of 121 patients with dermatomyositis. Medicine (Baltimore). 88(2):91–97CrossRefPubMed
9.
Zurück zum Zitat Lu X, Yang H, Shu X, Chen F, Zhang Y, Zhang S et al (2014) Factors predicting malignancy in patients with polymyositis and dermatomyositis: a systematic review and meta-analysis. PLoS One 9(4):e94128CrossRefPubMedPubMedCentral Lu X, Yang H, Shu X, Chen F, Zhang Y, Zhang S et al (2014) Factors predicting malignancy in patients with polymyositis and dermatomyositis: a systematic review and meta-analysis. PLoS One 9(4):e94128CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Zantos D, Zhang Y, Felson D (1994) The overall and temporal association of cancer with polymyositis and dermatomyositis. J Rheumatol 21:1855–1859PubMed Zantos D, Zhang Y, Felson D (1994) The overall and temporal association of cancer with polymyositis and dermatomyositis. J Rheumatol 21:1855–1859PubMed
11.
Zurück zum Zitat Hill CL, Zhang Y, Sigurgiersson B, Pukkala E, Mellemkjaer L, Airio A et al (2001) Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 357:96–100CrossRefPubMed Hill CL, Zhang Y, Sigurgiersson B, Pukkala E, Mellemkjaer L, Airio A et al (2001) Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 357:96–100CrossRefPubMed
12.
Zurück zum Zitat Buchbinder R, Forbes A, Hall S, Dennett X, Giles G (2001) Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study. Ann Intern Med 134:1087–1095CrossRefPubMed Buchbinder R, Forbes A, Hall S, Dennett X, Giles G (2001) Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study. Ann Intern Med 134:1087–1095CrossRefPubMed
13.
Zurück zum Zitat Stockton D, Doherty VR, Brewster DH (2001) Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: a Scottish population-based cohort study. Br J Cancer 85:41–45CrossRefPubMedPubMedCentral Stockton D, Doherty VR, Brewster DH (2001) Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: a Scottish population-based cohort study. Br J Cancer 85:41–45CrossRefPubMedPubMedCentral
14.
15.
Zurück zum Zitat Torres C, Belmonte R, Carmona L, Gómez-Reino FJ, Galindo M, Ramos B et al (2006) Survival, mortality and causes of death in inflammatory myopathies. Autoimmunity 39:205–215CrossRefPubMed Torres C, Belmonte R, Carmona L, Gómez-Reino FJ, Galindo M, Ramos B et al (2006) Survival, mortality and causes of death in inflammatory myopathies. Autoimmunity 39:205–215CrossRefPubMed
16.
Zurück zum Zitat Kuo CF, See LC, Yu KH, Chou IJ, Chang HC, Chiou MJ et al (2011) Incidence, cancer risk and mortality of dermatomyositis and polymyositis in Taiwan: a nationwide population study. Br J Dermatol 165:1273–1279CrossRefPubMed Kuo CF, See LC, Yu KH, Chou IJ, Chang HC, Chiou MJ et al (2011) Incidence, cancer risk and mortality of dermatomyositis and polymyositis in Taiwan: a nationwide population study. Br J Dermatol 165:1273–1279CrossRefPubMed
17.
Zurück zum Zitat Sigurgerisson B, Lindelof B, Edhag O, Allander E (1992) Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med 326:363–367CrossRef Sigurgerisson B, Lindelof B, Edhag O, Allander E (1992) Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med 326:363–367CrossRef
18.
Zurück zum Zitat Liu WC, Ho M, Koh WP, Tan AW, Ng PP, Chua SH et al (2010) An 11-year review of dermatomyositis in Asian patients. Ann Acad Med Singap 39:843–847PubMed Liu WC, Ho M, Koh WP, Tan AW, Ng PP, Chua SH et al (2010) An 11-year review of dermatomyositis in Asian patients. Ann Acad Med Singap 39:843–847PubMed
19.
Zurück zum Zitat Marie I, Hachulla E, Hatron PY, Hellot MF, Levesque H, Devulder B et al (2001) Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis. J Rheumatol 28:2230–2237PubMed Marie I, Hachulla E, Hatron PY, Hellot MF, Levesque H, Devulder B et al (2001) Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis. J Rheumatol 28:2230–2237PubMed
20.
Zurück zum Zitat Wakata N, Kurihara T, Saito E, Kinoshita M (2002) Polymyositis and dermatomyositis associated with malignancy: a 30-year retrospective study. Int J Dermatol 41:729–734CrossRefPubMed Wakata N, Kurihara T, Saito E, Kinoshita M (2002) Polymyositis and dermatomyositis associated with malignancy: a 30-year retrospective study. Int J Dermatol 41:729–734CrossRefPubMed
21.
Zurück zum Zitat Maoz CR, Langevitz P, Livneh A, Blumstein Z, Sadeh M, Bank I et al (1998) High incidence of malignancies in patients with dermatomyositis and polymyositis: an 11-year analysis. Semin Arthritis Rheum 27:319–324CrossRefPubMed Maoz CR, Langevitz P, Livneh A, Blumstein Z, Sadeh M, Bank I et al (1998) High incidence of malignancies in patients with dermatomyositis and polymyositis: an 11-year analysis. Semin Arthritis Rheum 27:319–324CrossRefPubMed
22.
Zurück zum Zitat Airio A, Kautiainen H, Hakala M (2006) Prognosis and mortality of polymyositis and dermatomyositis patients. Clin Rheumatol 25:234–239CrossRefPubMed Airio A, Kautiainen H, Hakala M (2006) Prognosis and mortality of polymyositis and dermatomyositis patients. Clin Rheumatol 25:234–239CrossRefPubMed
23.
Zurück zum Zitat Tiniakou Eleni, Mammen Andrew L (2017) Idiopathic Inflammatory myopathies and malignancy: a comprehensive review. Clin Rev Allerg Immunol 52:20–33CrossRef Tiniakou Eleni, Mammen Andrew L (2017) Idiopathic Inflammatory myopathies and malignancy: a comprehensive review. Clin Rev Allerg Immunol 52:20–33CrossRef
24.
Zurück zum Zitat Yang Z, Lin F, Qin B, Liang Y, Zhong R (2015) Polymyositis/dermatomyositis and malignancy risk: a metaanalysis study. J Rheumatol 42(2):282–291CrossRefPubMed Yang Z, Lin F, Qin B, Liang Y, Zhong R (2015) Polymyositis/dermatomyositis and malignancy risk: a metaanalysis study. J Rheumatol 42(2):282–291CrossRefPubMed
25.
Zurück zum Zitat Sparsa A, Liozon E, Hermann F, Ly K, Lebrun V, Soria P et al (2002) Routine vs extensive malignancy search for adult dermatomyositis and polymyositis: a study of 40 patients. Arch Dermatol 138:885–890CrossRefPubMed Sparsa A, Liozon E, Hermann F, Ly K, Lebrun V, Soria P et al (2002) Routine vs extensive malignancy search for adult dermatomyositis and polymyositis: a study of 40 patients. Arch Dermatol 138:885–890CrossRefPubMed
26.
Zurück zum Zitat Inoue M, Iwasaki M, Otani T, Sasazuki S, Noda M, Tsugane S (2006) Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Arch Intern Med 166:1871–1877CrossRefPubMed Inoue M, Iwasaki M, Otani T, Sasazuki S, Noda M, Tsugane S (2006) Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Arch Intern Med 166:1871–1877CrossRefPubMed
27.
Zurück zum Zitat Fiorentino DF, Kuo K, Chung L, Zaba L, Li S, Casciola-Rosen L (2015) Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ anti-bodies in adults with dermatomyositis. J Am Acad Dermatol 72:449–455CrossRefPubMedPubMedCentral Fiorentino DF, Kuo K, Chung L, Zaba L, Li S, Casciola-Rosen L (2015) Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ anti-bodies in adults with dermatomyositis. J Am Acad Dermatol 72:449–455CrossRefPubMedPubMedCentral
Metadaten
Titel
Clinical characteristics and prognosis of polymyositis and dermatomyositis associated with malignancy: a 25-year retrospective study
verfasst von
Kyoko Motomura
Hiroyuki Yamashita
Saeko Yamada
Yuko Takahashi
Hiroshi Kaneko
Publikationsdatum
23.08.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
Rheumatology International / Ausgabe 10/2019
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-019-04428-z

Weitere Artikel der Ausgabe 10/2019

Rheumatology International 10/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.